PBAC's latest decision on Dalteparin sodium: Recommended with restriction (2010). Considered for Management of symptomatic venous thromboembolism in a patient with a solid tumour(s).
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2010
Submissions
1
2010 → 2010
Eligible population
patients with a solid tumour(s) and symptomatic venous thromboembolism (VTE)
Therapy area
Other
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
Other
Key trials
CLOT, Deitcher 2006, Meyer 2002
Comparator
enoxaparin
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated